GSA Capital Partners’s Cocrystal Pharma COCP Stock Holding History

GSA Capital Partners’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,602	Closed	-$60K	–	1349
2021 Q1	$60K	Buy	+3,602	New	+$73.1K	0.01%	1024

Other funds holding COCP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

GSA Capital Partners's COCP Position: Q2 2021 in Review

GSA Capital Partners sold out of Cocrystal Pharma (COCP) in Q2 2021, closing a stake of 3,602 shares — an estimated $60K sold.

GSA Capital Partners first reported a position in COCP in Q1 2021 and held it in 1 quarter. The position peaked at $60K in Q1 2021. 42 funds tracked by Wall St. Rank hold COCP as of Q2 2021.

GSA Capital Partners reported no remaining Cocrystal Pharma position as of Q2 2021 after selling out during the quarter.
GSA Capital Partners sold 3,602 Cocrystal Pharma shares in Q2 2021, an estimated $60K.
GSA Capital Partners first reported a position in Cocrystal Pharma in Q1 2021 and held it in 1 quarter.
GSA Capital Partners's Cocrystal Pharma position peaked at $60K in Q1 2021.
42 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2021.

Based on GSA Capital Partners's 13F filing for Q2 2021, filed 5 Aug 2021.